JOHN VIERLING to Interleukins
This is a "connection" page, showing publications JOHN VIERLING has written about Interleukins.
Connection Strength
0.243
-
Hepatitis C virus viral assays in the direct-acting antiviral era. Clin Liver Dis. 2013 Feb; 17(1):27-45.
Score: 0.092
-
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010 Sep; 52(3):822-32.
Score: 0.078
-
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014 Dec; 61(6):1238-46.
Score: 0.026
-
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-na?ve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):524-37.
Score: 0.024
-
JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-na?ve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):514-23.
Score: 0.024